Swedish Orphan Biovitrum AB (OTCPINK:BIOVF) (STO:SOBI)

SUMMARY

Stockholm-based Swedish Orphan Biovitrum AB (OTCPINK:BIOVF) (STO:SOBI) last year purchased privately held, North Carolina-based Dova Pharmaceuticals for \$915 million. Through the deal Sobi acquired Doptelet (avatrombopag), an oral drug already approved to treat thrombocytopenia (very low platelet counts) in two indications, chronic liver disease (CLD) and chronic immune thrombocytopenia (ITP).

Doptelet competes with drugs from Novartis (NYSE:NVS) and Amgen (NASDAQ:AMGN) in the two indications above, but it owns the pole position to be the first thrombopoietin receptor (TPO) agonist to be approved to treat chemotherapy-induced thrombocytopenia (CIT). *SanaCurrents* assigns a pivotal sentiment that Sobi will report positive phase III data in the middle of 2020 for Doptelet in CIT.

Sobi, which has \$1 billion in revenue from sales of hematology and immunology drugs, had its eye on the CIT indication. To compete against Novartis' Promacta/Revolade (eltrombopag) and Amgen's Nplate (romiplostim), Sobi and Dova understood Dova would face stiff headwinds as a small biotech. However, because Sobi's marketing base in the US and Europe can push Doptelet into the market quickly, Sobi bought Dova. In fact, all Dova employees were retained after the acquisition and Dova shareholders stand to receive an additional \$1.50 per share in cash, once Doptelet is approved in CIT.

Doptelet owns several practical advantages over Promacta and Nplate, in addition to becoming the only drug to be indicated in CIT. Patients on Promacta need to be hospitalized, whereas Doptelet may not; Nplate need to be injected every week by a physician. Patients on Promacta must have failed prior treatments while Doptelet patients need to fail only one previous treatment. Promacta, an oral medication, also can only be used in patients with increased bleeding risks; Doptelet does not have that restriction in ITP.

While physicians and hospitals likely do not consider prescribing Promacta and Nplate off label to treat CIT as an egregious practice, regulators in Europe and the US increasingly ask why is the approved drug not used? And is the off label drug more expensive than approved drug? Promacta, which recorded \$1.17 billion in sales in 2018, costs about \$60,000 per year. Weekly dosing of Nplate for one year costs approximately \$55,250. Last June, Dova reduced the price of Doptelet to about 1/3 of the Promacta price.

THE EDGE

Sobi's purchase of Dova considerably minimizes the risk of a sputtering commercial launch of Doptelet. A common biopharma strategy is for a small company like Dova to gain approval or strong data in an orphan indication like CIT and wait for the partnership or acquisition offers to roll through the door. And while they wait, the share price barely moves higher. Or often slides.

Amarin (NASDAQ:AMRN) reportedly turned down a \$9 billion bid after it reported positive phase III data of its fish oil drug to treat heart disease in September 2018. After reaching \$22.87 per share in October 2018,

PROBABILITY SENTIMENT



Key Catalyst(s)

• Phase III data of Doptelet in CIT

Key Catalyst Date(s)

• Mid-2020

Key Executives

Guido Oelkers, President, CEO

Hakan Bjorklund, Independent Chairman of the Board

Mats-Olof Wallin, CFO, Senior VP

Armin Reininger, Senior VP, Medical and Scientific Affairs

Lars Dreioee, Senior VP, Chief Quality & Compliance Officer

Location

Tomtebodavagen 23A Solna 112 76 Sweden 46 86 97 20 00

Website

http://www.sobi.com



General Guidelines for SanaCurrents Strategy

In most situations, SanaCurrents partners take a position in a stock (or buy shares) shortly after a report on a catalyst is published. This is particularly true if the catalyst is within 90 days of the published report. For catalysts with horizons of 6-9 months, or longer, SanaCurrents anticipates the biopharma and device stocks from which it selects catalysts can rise or fall 20-30% in the months following the date of the published report. While buying at a dip, naturally, is preferred, SanaCurrents does not forecast or model in swings in share price prior to the catalyst. SanaCurrents' analytics score models the probability a compelling catalyst will be positive. SanaCurrents positive expects а announcement regarding a catalyst will drive a company's stock to higher level than the price on the date of the report, based on the company's value and capital structure when the report was published. That said, subscribers should exercise their preferred, individual discipline when timing trades, buy or sell, regarding the catalyst forecast.

Swedish Orphan Biovitrum AB (OTCPINK:BIOVF) (STO:SOBI)

THE EDGE cont'd

Amarin's shares since have traded between \$13 per share and \$25 per share. Amarin's market cap has ranged between \$6 billion and \$7 billion over the last 15 months.


The principals at Dova embraced a different approach, agreeing to the Sobi offer in order to move Doptelet more rapidly into the market for all three indications. Analysts estimate Doptelet could capture up to \$1.88 billion in CLD and ITP, because of its better profile. Sobi estimates the CIT market for Doptelet to be \$2 billion in the US alone; analysts' forecasts call for Doptelet to rein in approximately \$600 million of that total.

In addition, neither Novartis nor Amgen have made significant progress in seeking formal approval for CIT.

The phase III trial of Doptelet in CIT is a double-blind, placebo-controlled test of the efficacy and safety in 120 subjects with active non-hematological cancers, such as ovarian, lung and bladder, who develop CIT (platelet count <50K/ μ L) during the previous cycle of chemotherapy. The primary endpoint is to measure the proportion of subjects who do not require platelet transfusion, a dose reduction in chemotherapy by 15%, or a chemotherapy delay of more than four days.

In the Doptelet (avatrombopag) phase III trial to treat ITP, avatrombopag administration resulted in a platelet count of at least 50,000 per μ L at day 8 of therapy for most patients with ITP. Avatrombopag appeared to be superior to placebo for maintaining platelet counts in the target range during the 6-month target period.

Given the success of Doptelet (avatrombopag) in two previous trials, *SanaCurrents* expects the drug will be able to replicate previous results in maintaining platelet counts in cancer patients.



Swedish Orphan Biovitrum AB (OTCPINK:BIOVF) (STO:SOBI)

Swedish Orphan Bio	ivitrum AB			SEK	172.15	1,85	1.06%	GEO	5	OBI.ST		7.90
Country	Owndern				Next FQ/F	H End Date	Dec 31, 2019	8,3004	87.00			\$12
Ixchange	Stockholm Stock learns	0.00			Next F	Y End Date	Dac 31, 2010	7,900	Λ			
GICS Sector	Health Care				Next ear	mings Date	Feb 13,2020	1,000	10			517
GICS Industry	Billiofreelogy				Latest ea	mings Date	0+31,2019	Print	1 17			
Currency	SEK							6.800	r l	AN		512
General Information					*M 100	hoto (JSD) ence	of per share data	6.000 M	1 143	and .	A	10.75
Price (Province Classe)	172.1E				Div. Yield, Last	your (FYD)		1,000		1 101	Red	1 512
Price . 57 Week High	254.10				Shares Outstan		200.9 6464	in the second			Ma	C.A.
Price - Carrent vs 52wk High	20.033				Short laterest S	1.000		Taxe Link.				\$21
hice - SZ Week Law	144.70				Si % of 0.5			um Children Lin	ALCORE MA	C D v Aid		
hice - Current vs 52wk Low	10.97%				Marinet Capitalia	nation	6312					- <u>Min</u>
leta Sampling last 1y, Daily		· Environ (1)	Di Stockhim			1000		11-Apr 2018	DAg 201 D4	a:201 8-May-301	19-540-818	10.64-302
					Interprise Valu		8,150	and the second second	tragent av	etter sadver	propaga	
stimates revision momentu	m					'n mhotal	ISD, wooget EPS	Per Share Metrics	FY-2	FY-1	FM	Th USD
	Last reported FY		Curnet Year F	11	0	Reat Year 5		Book Value:	10.00	24 BB	11.40	50 m
	Cart reporting 1 a	firsth ago	Josth ago	Today	firsth ago	Jinti ago	Today	Free Cash Flow	0.06	2.43	6.001	0.0
Tonservavis date		8/1/2019	11/1/2019	2/1/2/020	8/1/2019	11/1/2019	2/1/2020	Dividend:	0.00	8.42	0.00	1.0
Toniseriava date Tevenine	1,057	1.420	11/1/2019	2/1/2020	1,556	11/1/2019	202020	Earnings (EPS):	100	4.25	893	10.4
	(30)	-2.76	-1.25	169	-10.475	-0.0%	1342	counds (cr.st	0.001	4.8	845	10.8
% diff to today Grass Profit			1.084	1.000				Valuation ratios		_		
	773	1,001		2000	1,300	1,170	1,109	Banana and a state	LTM		1944	1444
6 diff to lo day		-1.46	-1.00	17-	-1.0%	-01%	1.12			NTM	FY1	FY
307	-	- 440	434	435	611	471	464	EVSales	4.94	391	424	35
% diff to to day	100	-0.9%	0.4%		-11.28	-318	-	EVEBITDA	12.5 1	2000	100 (9.4
EB/7DA	415	617									14.7 #	
				500	.000	647	1.12	P/E	0.51	13.4 +		
		-1.00	-0.0%		-7.00	-2.04		PE to Growth (PEG)	WARE AND OTHER	weite painmater :		
5PS	1 maa	-3.56	1.12) be	-7 00 1 22	-2 0%-	(11)	PE to Growth (PEG) EVECE	well assessed	weath parameter a	Ad parameter 1	fid parametr
EPS	(1)	-1.00	-0.0%		-7.00	-2.04		PE to Growth (PEG) EV/FCF P/Sales	WARE AND OTHER		Ad parameter 1	fid paradieth 2.4
EPS	100	-3.56	1.12		-7 00 1 22	-2 0%-		PE to Grawth (PEG) EVFCF PISalas P/DV	well assessed	weath parameter a	Ad parlamenter in 32 a 30 a	1d paramete 24 28
SPE 16 difto today		-3.56	1.12) De	-7 00 1 27 -14 09	-2 0% 1 20 -4 78	1.229	PE to Growth (PEG) EV/FCF P/Sales	well assessed	weath parameter a	Ad parameter 1	1d paramete 24 28
SPE 16 difto today		-16	-0.0% 1.12 .30%	1 DE	1 21 -1403 A, except dilate	2	(m)	PE to Growth (PEG) EVECE PISales POV P/Tangible BV	1993.12 patrice for 4.2 - 1999	weath parameter a	32 s 30 s 30 s 23 s	14 paramete 34 28 27
ps 14 difto Isoday Consolidated Income Statem	ent.	-1 A -1 A -1 A	-0 0% 112 -30%	1 DE "to miliona (/) FY 2	-7 00 1 27 -14 00 -14 00 -14 -14 00 -14 00 -	-2 (***) 1 (20) -4 (***) 4 (***) (***) 6 (***) (***) 6 (***)	1.229	PE to Grawth (PEG) EVFCF PISalas P/DV	1993.12 patrice for 4.2 - 1999	weld promities	37 s 38 s 38 s 38 s 38 s 23 s	14 paratesta 24 27 20
peg 9. difto todar Consolidated Income Statem Pasca and othe	enti FY 5 12/31 2013	0.00 1.10 1.00 FY 4 t2012844	40 0 013 400 400 600 600 600 600 600 600 600 600	his In million (// FY 2 12/31/2016	-7 00 1 21 -1400 	100 4.78 6.78 6.78 6.78 6.78 6.78 6.78 6.78 6	(III) Syr-CAGR	PE to Growth (PEG) EVECF PSalas PULV P/Tangible BV Consolidated Balans	1993.12 patrice for 4.2 - 1999	50 LE provinsion 1 33 x FY 2	At priority 1 27 s 20 s 23 s 23 s 23 s 24 25 25 25 25 25 25 25 25 25 25 25 25 25	14 paranet 24 27 27 27 27 27 27
pre 14 dif to Soday Consolidated Income Statem Miccolection	ent. FY 5 12/31/0913 234	0.0 1.10 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	009 112 309 573 5231605 83	1.00 1.00 12/31/2016 12/31/2016	-7 (%) 22 465 27 27	2 (% 1.00 2.00 2.00 5.00 5.00 1.00 1.00 1.00 1.00 1.00 1	LIII Second Courses Syr-CACR	PE to Growth (PE G) EVECF PiSales PUT P/Tangible BV Consolidated Balance Person and cate	1993.12 patrice for 4.2 - 1999	weld promities	37 s 38 s 38 s 38 s 38 s 23 s	14 paranet 24 27 27 27 27 27 27
ppg 16 dff to today Constellidated Income Statem Period and othe Sales Sales	ent. FY 5 12/31/0913 3/4 12/31/0913	0.6 1.10 1.0 1.0 1.0 1.0 10 10 10 10 10 10 10 10 10 10 10 10 10	60% (12) -30% FY3 12012015 183 285	1.00 10 million 1/2 12/31/2016 203 477	-1 (%) 22 46% 46% 120 120 120 120 120 120 120 120	20% 1.0 3.% 4755 (add) 4 6795 (add) 4 6795 (add) 4 6795 (add) 4 6795 (add) 4 6795 (add) 4 6 779 (add) 4 779 (add)	UII Syrchae 3175 318	PE to Growth (PE G) EVECF P/Sales PUTV P/Tangible BV Convolidated Electro Among and cate Cash & ST Invalments	1993.12 patrice for 4.2 - 1999	FY 2 12010016	27 + 304 234 234 234 24 24 24 24 24 24 24 24 24 24 24 24 24	24 26 27 27 27 27 27 27 27 27 27 27 27 27 27
peg k off to Soday Rentralidated income Statem Yelso on othe See Jena Income BHTDA (HQ)	ent. 12/21/0013 324 32 32 32 32 32 32 32 32 32 32 32 32 32	0.% 1.15 -1.% FY4 12012014 30) 28 40	60% (1) -30% FY3 12012015 83 238 55	1.05 10 million (// FY 2 12 31 2316 427 134	-7.00 1.23 -1405 0.0000000000 FY 4 12012017 702 535 334	20% 1.30 3.5% 6201000 62012000 12012000 12012000 12012000 12012000	LIII Second Courses Syr-CACR	PE to Growth (PE G) EVECE P/Sales POIV P/Tangible BV Consolidated Belance Consolidated Belance Consolidated Belance Consolidated Belance Consolidated Belance	1993.12 patrice for 4.2 - 1999	FY 2 12/31/00/16 12/31/00/16	41 provinster 1 37 + 30 + 33 + 23 + 23 + 24 23 + 24 24 24 24 24 24 24 24 24 24 24 24 24	14 parameter 24 25 27 12:31:201 1,20
PE k diffo Soday Conkolid Ated Income Statem Vision Vision Seco Inna Income BITDA (adj.) BIT (adj.)	ent. 12/21/2013 334 97 10	0.00 1.10 120 12012014 12012014 12012014 120 120 120 120 120 120 120 120 120 120	009- 1.12 309- 593 12012015 133 236 65 13 13	1.05 1000 000 000 1201 0016 000 407 104 100	7 % 1 27 1405 0 mont 4140 12012017 12012017 555 284 167	2 % 1 20 47% 6 6 7 (0) 6 7 (0) 12 (1 20 98 (0) 12 (1 20 98) (0) 12 (1 20 98) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	UII Syrchae 3175 318	PE to Grawth (PE G) EVECF PSales PUTV PT anglithe OV Consolidated Balance Person and cate Cash & ST Invadments Inventory Tatal Assies	1993.12 patrice for 4.2 - 1999	FY2 12310016 12710016 12710016	27 s 37 s 30 s 23 s 23 s 24 27 12/21/2817 12/21/2817 10/53 10/53	14 paralel 34 28 27 12:01:201 12:01:201 12:010 12:01 1
prg 6. dffto todar Consolidated Income Statem Pator en/ oth See See Bana (noume BattoA (adj.) Banaga Bafore Tac (adj.)	ert. F7.5 12/91/913 334 90 7 10 10	0 % 1 15 1 % 10 10 10 10 10 10 10 10 10 10 10 10 10	009- 1.12 308- 5743 12012015 123 225 225 225 225 225 225 225 225 225 2	1.05 10 million (10 12 million (10 1	7 % 1 27 1405 Fy 4 12012017 700 555 544 107 170	2 % 1 20 1 20 1 20 1 20 1 20 1 20 1 20 1 20	UII Syrchae 3175 318	PE to Growth (PE G) EVECF PSales PUTV P/T anglitik 0V Connectificated Extense Ferror and all Connectificated Extense Ferror and all Invertory Tatal Assess Comment Liabilities	1993.12 patrice for 4.2 - 1999	FY2 12/31/00/16 12/31/00/16 12/31/00/16 12/31 12/31 12/31	44 promoter 1 27 4 2014 2316 2316 2014 2316 2417 1023 10230 2305 2305	24 26 27 27 1231201 1231201 1231201 1231201
prg k dffto todar Centrolidated Incom a Statem Incom a State Stee Stee Stee Bat (a4) (Bat (a4) (Samgs Enfore Tax (a4) (Samgs Enfore Tax (a4) (ent FY 5 12/31/0913 334 50 7 10 10 10	0 0 1 10 1 20 1	008 1.12 305 573 12012015 103 205 103 103 103 103 103 103 103 103 103 103	1.00 1100 1100 1100 1100 1100 1100 1100	7 % 1 27 1405 24 2012017 702 555 244 107 179 110	2000 1.20 2.75 2.75 2.75 2.75 2.75 2.75 2.75 2.75	UII Syrchae 3175 318	PE to Growth (PE G) EVECF P/Sales PULV P/Tangible BV Connectidated Balance Connectidated Balance Connectidated Balance Connectidated Balance Tatal Asses Corrent Labilities Total Debt	1993.12 patrice for 4.2 - 1999	FY2 12310 FY2 12310016 870 5374 1788 104	Ad promitie 1 274 201 234 12342017 12342017 10,53 10,553 23,65 5	24 28 27 27 1231201 1231201 1231201 1231201
prg k diffo Soday Consolidated Incom a Statem Micores/ode Sales Dross Income BBTDA (sk) (BBT (sk) (sk) (BBT (sk) (sk) (sk) (sk) (sk) (sk) (sk) (sk)	ant. 17/5 12/31/0013 334 354 354 354 354 354 354 354 355 355	2.% (15) 1.% PY 4 12012PH 30) 226 4 4 12 12 12 12	008 1.12 305 573 12012015 83 285 65 12 12012015 12 12012015 12 12 12 12 12 12 12 12 12 12 12 12 12	1.05 74 million (1/2 Fy 2 1201/2016 939 447 154 154 152 152 153 155 155 155 155 155 155 155 155 155	700 127 1460 1714 12012017 700 555 204 107 170 130	- 2 % 1 20 - 3 % - 5	(13)	PE to Growth (PE G) EVECF P/Sales PUSY P/Tangible BV Connectidated Extense Freeson and Cash & ST Invatments Inventory Total Assets Carrent Lishifies Total Debt Total Debt Total Lishifies	ereid an arceler ann 4.2 - ann 4.5 March	FY 2 12310 FY 2 12310016 070 5374 1700 010 4 600	37 s 30 s 23 s 23 s 23 s 23 s 23 s 23 s 23 s 23	24 26 27 27 1231201 120 12,0 12,0 12,0 12,0 12,0 12,0 1
is diff to today EPS is diff to today Consolidated line ome Statem Pater and oth Selec Selec Bert (a4) Earnage Before Tax (a4) Earnage Before Tax (a4) Earnage Before Tax (a4) Earnage Before Tax (a4) Cammon Shaka	ent FY 5 12/31/0913 334 50 7 10 10 10	0 0 1 10 1 20 1	008 1.12 305 573 12012015 103 205 103 103 103 103 103 103 103 103 103 103	1.00 1100 1100 1100 1100 1100 1100 1100	7 % 1 27 1405 24 2012017 702 555 244 107 179 110	2000 1.20 2.75 2.75 2.75 2.75 2.75 2.75 2.75 2.75	UII Syrchae 3175 318	PE to Growth (PE G) EVECF P/Sales PULV P/Tangible BV Connectidated Balance Connectidated Balance Connectidated Balance Connectidated Balance Tatal Asses Corrent Labilities Total Debt	ereid an arceler ann 4.2 - ann 4.5 March	FY2 12310 FY2 12310016 870 5374 1788 104	Ad promitie 1 274 201 234 12342017 12342017 10,53 10,553 23,65 5	14.0 34 26 27 12.312011 12.01 12.10
EPE & diffo toda: Consolidated Income Statem Pasce and oth Sales Data Income BITOA (adj.) BITOA (adj.) Estings Enfore Test (adj.) Interest EPS (adj.) Samen Shares	ert. 12/21/0413 334 367 77 10 10 10 10 10 10 10 10 10 10 10 10 10	2.% (15) 1.% PY 4 12012PH 30) 226 4 4 12 12 12 12	008 1.12 305 573 12012015 83 285 65 12 12012015 12 12012015 12 12 12 12 12 12 12 12 12 12 12 12 12	1.05 74 million (1/2 Fy 2 1201/2016 939 447 154 154 152 152 153 155 155 155 155 155 155 155 155 155	700 127 1460 1714 12012017 700 555 204 107 170 130	- 2 % 1 20 - 3 % - 5	(13)	PE to Growth (PE G) EVECF P/Sales PUSY P/Tangible BV Connectidated Extense Freeson and Cash & ST Invatments Inventory Total Assets Carrent Lishifies Total Debt Total Debt Total Lishifies	rest and only 4.7. min a Sheet	FY 2 12310 FY 2 12310016 070 5374 1700 010 4 600	27 + 2011 233 - 2021 233 - 2021 2791,2817 10,291,2817 10,291,2817 2,291,2817 10,291,2817 4,292 4,292 4,292	24 26 27 12:01:201 10:01:201 10:01:2
PE L diffo to day Consolidated Income Statem Income (oth Income State BTDA (adj.) BTDA (adj.) BTDA (adj.) Inter (adj.) Inter EPS (adj.) Inter EPS (adj.) Inter EPS (adj.)	ert. 12/21/0413 334 367 77 10 10 10 10 10 10 10 10 10 10 10 10 10	2.% (15) 1.% PY 4 12012PH 30) 226 4 4 12 12 12 12	008 1.12 305 573 12012015 83 285 65 12 12012015 12 12012015 12 12 12 12 12 12 12 12 12 12 12 12 12	1.05 74 million (1/2 Fy 2 1201/2016 939 447 154 154 152 152 153 155 155 155 155 155 155 155 155 155	700 127 1460 1714 12012017 700 555 204 107 170 130	- 2 % 1 20 - 3 % - 5	(13)	PE to Growth (PE G) EVECF PSales POIV PT anglish: BV Consolidated Balance Cash & ST Inventory Tatal Assers Carrent Lishiftee Tatal Lishiftee Tatal Starsholders Equ	rest and only 4.7. min a Sheet	FY 2 12310 FY 2 12310016 070 5374 1700 010 4 600	27 + 2011 233 - 2021 233 - 2021 2791,2817 10,291,2817 10,291,2817 2,291,2817 10,291,2817 4,292 4,292 4,292	24 26 27 12:31:201 12:31:2
PE Latific to dex consolidated income Statem excession area BTDA (a4) BT (a4) BT (a4) arrays Before Tax (a4) (arrays Before Tax (a4)) et Acceme (a4) Excesse (a4) second Status Arrgios & Profitability Ratios	ert. 12/21/0413 334 357 10 10 10 10 10 10 10 10 10 10 10 10 10	2.6 (15) (15) (20) (20) (20) (20) (20) (20) (20) (20	678 112 376 573 12012005 183 288 17 17 18 10 17 17 18 10 10 10 10 10 10 10 10 10 10 10 10 10	1.05 1.05 12210016 235 427 154 154 154 155 155 155 155 155	-700 127 -4400 -914 -914 -914 -914 -914 -914 -914 -914	2 (%) 1.20 5.75 5.70 1.201	(11) Constant Shares SyrCACR 21 75 21 75 0.15 0.15	PE to Growth (PE G) EVECF PSales POIV PT anglish: BV Consolidated Balance Cash & ST Inventory Tatal Assers Carrent Lishiftee Tatal Lishiftee Tatal Starsholders Equ	rest and only 4.7. min a Sheet	FY2 12/31/2016 12/31/2016 12/31/2016 12/31	27 + 2014 2014 2014 2014 2014 2014 2014 2014	24 28 27 1201201201 1201200 1201200 1201200 1201200 1201200 1201200 1201200 1201200 1201200 1201200 1201200 1201200 1201200 1201200 1201200 1201200 100000000
PE L dffto today consolidated loccome: Statem inter any ode inter i	ent FY 5 12/21/0913 334 334 334 334 334 334 334 334 334 3	2.6 (15) (15) (20) (20) (20) (20) (20) (20) (20) (20	608 112 305 5743 12012005 103 205 10 10 10 10 10 10 10 10 10 10 10 10 10	1.05 10 millional (/2 FY 2 12 millional (/2 12 millional) 12 millional 12 millio	7 000 1 27 24400 1944 192012000 702 564 364 107 709 104 105 209 209 209 209 209 209 209 209 209 209	2000 1.20 570 12012009 12012000 12012000 12012000 12012000 12012000 12012000 12012000 12012000 12012000 12012000 1201200000000	(11) Control statut Syr-CAGE 21 7% 21 7% 01 1% 0.1% 0.3%	PE to Growth (PE G) EVECF PSales PUTV P/Tangible 0V Consolidated Balance Cash & ST Invation Invertory Tatal Assass Carrent Lish New Tatal Casha	rest and only 4.7. min a Sheet	FY2 12/31/0016 12/31/0016 12/31/0016 12/31	37 s 30 s 30 s 30 s 30 s 30 s 30 s 30 s 30	24 28 27 1201201201 1201200 1201200000000
PE E diffo today Controllidated line on a Statem inconer of the sites incone (add) inconer	ent. FY 5 12/31 (913) 334 334 334 334 334 334 334 334 334 3	2.6 (15) (15) (25)(20)4 (20) (26) (4) (20) (26) (4) (12) (12) (12) (12) (12) (12) (12) (12	608 112 305 573 12312015 303 225 01 12 12312015 12312015	1:05 1:07 (12) 12:01 (20)6 12:01 (20)6 1	-700 127 -4400 -914 -914 -914 -914 -914 -914 -914 -914	2 00 1,20 3,75 4,52 4,52 1,201 2,21 4,15 3,14 4,15 3,14 4,15 3,14 4,15 3,14 4,15 3,14 4,15 3,14 4,15 3,14 4,15 3,14 4,15 3,14 4,15 3,14 4,15 3,14 4,15 3,14 4,15 3,14 4,15	(13) Syr-CACR 25 7% 31 2% 01.1% 0.3% w. kmt Sy memoge (%pts).	PE to Growth (PE G) EVECF PSales PULV P/Tangible BV Connectidated Balance Connectidated Balance Connectidated Balance Connectidated Balance Total Asses Carrent Labilities Total Debt Total Debt Total Debt Total Debt Total Debt Total Debt Total Statebolities Ego Connectidated Cases F	rest and only 4.7. min a Sheet	FY 2 12/31/00/16 12/31/00/16 19/18 19/18 19/18 5.316 5.316 5.316 5.316	37 s 30 s 23 s 23 s 23 s 23 s 23 s 23 s 23 s 23	24 28 27 1231201 1231201 1231201 1231201 1231201 1231201 1231201 1231201 1231201 1231201 1231201 1231201
PE L diffo today Controllidated line on a Statem Inter any othe Sites Inter Come BIT (adj) Inter toome (adj) Inter toom	ent. FY 5 12/31/0413 334 357 10 10 10 10 10 10 10 10 10 10 10 10 10	2.6 (15) (15) (15) (15) (15) (15) (15) (15)	608 1.12 305 573 12312015 83 28 83 28 12 12312015 12312015 1231205 1235	115 115 121 12211/2016 123 123 123 123 123 123 123 123	-786 127 -1460 -1744 -12012007 -782 -585 -284 -1770 -782 -389 -784 -12012007 -7125	2 % 1.20 3.75 570 12312099 1,01 22312099 1,01 223 415 355 355 355 355 225 225 225 22	(13) Syr-CAGR 25.7% 31.2% 0.1% 0.3% 0.3% 0.3% 0.3%	PE to Growth (PE G) EVECF P:Sales PUT P:Tangible BV P/Tangible BV Connectidated Bolance Cash & ST Invatments Inventory Total Assets Carrent Lishifies Total Debi Total Debi Total Debi Total Shareholdes Ego Consectabled Gests F Perceled date NetTropme	rest and only 4.7. min a Sheet	PY 2 23 x 23 x 12310016 007 3374 13974 13974 13974 5366 FY 2 12010016 007	Adjanameter 1 323 s 303 233 233 234 234 234 234 234 234 234 3 5 4,353 5 4,353 5 4,353 5 7 4,253 2,344 5 7 4,2534 4,253 4,254 4,253 4,254 4	24 24 26 27 1231201 123120000000000
PE L diffe to dec Consolidated Income Statem Weater (de Income (de) Income (al) Intel PS (al) Internor Shares Statistic States Income (de Income (de In	ent FY 5 12/31/0913 334 357 10 10 10 10 10 10 10 10 10 10	0.00 (10) (10) (10) (10) (10) (10) (10) (1	009 1.12 305 FY3 12012015 12 12012015 12 12012005 12012005 12012005	105 105 107 107 107 107 107 107 107 107	700 127 1460 1974 12012007 700 555 344 107 108 209 209 209 1055 1355	2 % 1.20 3.75 4.75 4.15 1.20 1.201 2.21	(13) Syr-CAGR 21 7% 31 2% 0.1% 0.3% www.lant Sy mercage.(Syte) 11 (a) 4 (a) 4 (a)	PE to Growth (PE G) EVECF PiSalas PUSY PiTangible BV Consolidated Editors Consolidated Editors Cash & ST Invalments Inventory Total Acade Cash & ST Invalments Inventory Total Acade Consolidated Editors Total Statistics Total Statistics Total Statistics Total Statistics	rest and only 4.7. min a Sheet	PY 2 23 x FY 2 12010916 077 5374 12010916 00 4 x09 5,365 FY 2 120102016 007 4 x19 5,365	Adjanameter 1 37 + 303 234 234 294 12342847 192342847 192342847 5 4,292 6,294 192342847 193448 193448 19344847 19344847 19344847 193448 19344847 193447 19347 1934	24 25 27 12012011 1201200 1201200000000
PES & dffo todar Consolidated Income Statem Price end ode See See See Ser Set (adj) Earling Ebfore Taribility Earling E	ent FY 5 12/31/0913 334 97 77 10 10 10 10 10 10 10 10 10 10	0.5 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	6Y3 5Y3 12012015 12012015 120 12012015 12 12012015 12012015 12015 12015 12015 12015	1.05 1.05 12210016 025 025 025 025 025 025 025 025	- 786 127 - 4455 - 79 4 12012017 710 564 - 710 564 - 710 - 710	2 (%) 1.20 5 (%) 1201/2009 1201/2009 1201/2009 1201/2009 1201/2009 1201/2009 1201/2009 1201/2009 1100/9 10	(11) Conserve schwarz Syr-CAGR 27,75 37,45 0,15 0,15 0,35 ve. keit Sy everage (5,pt) 3,100 5,100 5,100 5,100 5,100	PE to Growth (PE G) EVECF PSales PUTV PT anglithe BV Consolidated Balance Cash & ST Invariants Inventory Tatal Assars Carrent Liskitikes Tatal Shareholders Ego Consolidated Gesh F Percod and other NetTroome DSA Dhange in WC	rest and only 4.7. min a Sheet	FY2 12/31/00/16 12/31/00/16 19/31 19/31 6/04 4.6/04 5.160 FY2 12/31/00/16 4.41 4.41 4.41 4.41 4.41 4.41 4.41 4.	27 + 2011 2011 2011 2011 2011 2011 2011 201	24 26 27 1201/281 120 1201/281 120 12,000 12,00 12,000 10,000 10,000 1
prg k diffo Soday Consolidated Income Statem Percenent othe Sales S	ent FY 5 12/21/2013 334 55 7 7 10 10 10 10 10 10 10 10 10 10 10 10 10	2.5 (15) (15) (15) (15) (15) (15) (15) (15	673 112 305 12012005 12012005 12012005 12012005 12012005 12012005 1201205	1.05 Varmilized (// FY2 1221/0916 005 427 1231/0916 005 005 005 005 005 005 005 00	- 700 127 - 4455 - 4455 - 744 - 700 -	20% 1.20 5.79 12012099 12012099 12012099 12012099 12012099 22120 2201209 1201209 1201209 1201209 1201209 1201209 1201209	(13)	PE to Growth (PE G) EVECF PSales PUTV PT angletic OV Consolidated Balance Cash & ST Investments Inventory Tatal Assess Carrent Lish Men Tatal	In Statement	FY2 12/31/2016 12/31/2016 13/31 17/37 602 4,609 5,365 FY2 12/35/2016 607 4,411 4,209 4,411 4,209 4,411 4,209 4,411 4,209 4,411 4,209 4,411 4,414	27 + 30 + 30 + 30 + 30 + 30 + 30 + 30 + 30	24 26 27 1201201 1201201 1201201 1201201 1201201 201201 241 25 250 250 250 250 250 250 250 250 250
PE L dffto today Consolidated Research Statem whore any other area from income BITO (adj.) BIT (adj.) BIT (adj.) Interf EPS (adj.) Anyone (adj.) Interf EPS	ent FY 5 12/31/0413 334 334 334 334 334 334 334 345 575 52/31/0413 52/31/31 52/31 52/5 52/5 52/5 52/5 52/5 52/5 52/5 52/	2.% (15) (15) (20) (20) (20) (20) (20) (20) (20) (20	608 112 305 12012005 183 285 12 12012005 12 12012005 1225 1225 1225	1.05 1	- 700 127 - 4465 - 944 -	2000 1.20 2.75 2.71 2.21 2.21 2.21 2.21 2.21 2.21 2.21	(13) Syr-CACR 25.7% 27.7% 07.7% 07.7% 0.7% 0.7% 0.7% 0.7% 0.7	PE to Growth (PE G) EVECF PSales PUTV PT angible BV Connected and Connected and Connected and Connected and Connected and Connected and Total Connected Total Connected Connected and Connected and Co	In Statement	Private provide a series of the series of th	27 + 30 + 30 + 30 + 30 + 30 + 30 + 40 + 40 + 40 + 40 + 40 + 40 + 40 + 4	24 28 27 1201201 1201201 1201201 1201201 1201201 241 201201 241 201201 241 201201 241 201201 241 201201 241 201201 241 201201 241 241 241 241 241 241 241 241 241 24
DPS N dffo today Consolidated Income Statem Peter and date Sees Sees Detrait (date Detrait (date) Detrait (date) Detrait (date) Detrait (date) Detrait (date Detrait (date Detrait (date Detrait (date) Detrait	ent. FY 5 12/31/0013 334 357 77 10 10 10 10 10 10 10 10 10 10	23% (15) (15) (27) (27) (27) (27) (27) (27) (27) (27	608 1.12 305 573 12012015 12012015 12012005 12012005 12012005 12012005 12012005 1201205 10	1.05 10 million (//) 12 million (/) 12 mill	-786 127 -446 PM 12012007 782 586 787 782 782 782 783 100 288 PM 12012007 7155 555 5225 555 5225 555 5225 555 52555 5255 5255 52555 5255 5255 5255 5255 5255	2 00 1.20 3.75 4.20 1.20 4.12 1.20 1.20 4.12 3.14 2.21 5.21	(12) Syr-CAGR 25.7% 31.2% 0.1% 0.1% 0.3% 0.3% 0.3% 0.3% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5	PE to Growth (PE G) EVECF PSales PUIV P/Tangible BV P/Tangible BV Consolidated Balance Cash & ST Invatrients Inventory Tatal Asses Carrier Labilities Tatal Calcillities Tatal Calcillities Consolidated Calcillities Disk Disk Cash Free Operations Capital Expenditures	In Statement	Private provide a series of the series of th	27 + 30 + 30 + 30 + 30 + 30 + 30 + 40 + 40 + 40 + 40 + 40 + 40 + 40 + 4	24 26 27 27 1231201 120 12,0 12,0 12,0 12,0 12,0 12,0 1

Disclaimer

Please be advised that GeoInvesting[™] is strictly a research and publishing firm, of general and regular circulation, which falls within the publisher's exemption to the definition of an "investment advisor" under Section 202(a)(11)(A) – (E) of the Securities Act (15 U.S.C. 77d(a)(6) (the "Securities Act"). GeoInvesting™ is not registered as an investment advisor under the Securities Act or under any state laws. None of our trading or investing information, including the Content, GeoInvesting™ Email, Executive Casts and/or content or communication (collectively, "Information") provides individualized trading or investment advice and should not be construed as such.

Swedish Orphan Biovitrum AB (OTCPINK:BIOVF) (STO:SOBI)

Accordingly, please do not attempt to contact GeoInvesting[™], or SanaCurrents[™], its members, partners, affiliates, employees, consultants and/or hedge funds managed by partners of GeoInvesting[™] (collectively, the "GeoInvesting[™] Parties") to request personalized investment advice, which they cannot provide. The Information does not reflect the views or opinions of any other publication or newsletter.

We publish Information regarding certain stocks, options, futures, bonds, derivatives, commodities, currencies and/or other securities (collectively, "Securities") that we believe may interest our Users. The Information is provided for information purposes only, and GeoInvesting[™] is not engaged in rendering investment advice or providing investment-related recommendations, nor does GeoInvesting[™] solicit the purchase of or sale of, or offer any, Securities featured by and/or through the GeoInvesting[™] Offerings and nothing we do and no element of the GeoInvesting[™] Offerings should be construed as such. Without limiting the foregoing, the Information is not intended to be construed as a recommendation to buy, hold or sell any specific Securities, or otherwise invest in any specific Securities. Trading in Securities involves risk and volatility. Past results are not necessarily indicative of future performance.

The Information represents an expression of our opinions, which we have based upon generally available information, field research, inferences and deductions through our due diligence and analytical processes. Due to the fact that opinions and market conditions change over time, opinions made available by and through the GeoInvesting[™] Offerings may differ from time-to-time, and varying opinions may also be included in the GeoInvesting[™] Offerings simultaneously. To the best of our ability and belief, all Information is accurate and reliable, and has been obtained from public sources that we believe to be accurate and reliable, and who are not insiders or connected persons of the applicable Securities covered or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer. However, such Information is presented on an "as is," "as available" basis, without warranty of any kind, whether express or implied. GeoInvesting[™] makes no representation, express or implied, as to the accuracy, timeliness or completeness of any such Information or with regard to the results to be obtained from its use. All expressions of opinion are subject to change without notice, and GeoInvesting[™] does not undertake to update or supplement any of the Information.

The Information may include, or may be based upon, "Forward-Looking" statements as defined in the Securities Litigation Reform Act of 1995. Forward-Looking statements may convey our expectations or forecasts of future events, and you can identify such statements: (a) because they do not strictly relate to historical or current facts; (b) because they use such words such as "anticipate," "estimate," "expect(s)," "project," "intend," "plan," "believe," "may," "will," "should," "anticipates" or the negative thereof or other similar terms; or (c) because of language used in discussions, broadcasts or trade ideas that involve risks and uncertainties, in connection with a description of potential earnings or financial performance. There exists a variety of risks/uncertainties that may cause actual results to differ from the Forward-Looking statements. We do not assume any obligation to update any Forward-Looking statements whether as a result of new information, future events or otherwise, and such statements are current only as of the date they are made.

You acknowledge and agree that use of GeoInvesting's[™] Information is at your own risk. In no event will GeoInvesting[™] or any affiliated party be liable for any direct or indirect trading losses caused by any Information featured by and through the GeoInvesting[™] Offerings. You agree to do your own research and due diligence before making any investment decision with respect to Securities featured by and through the GeoInvesting[™] Offerings. You represent to GeoInvesting[™] that you have sufficient investment sophistication to critically assess the Information. If you choose to engage in trading or investing that you do not fully understand, we may not advise you regarding the applicable trade or investment. We also may not directly discuss personal trading or investing ideas with you. The Information made available by and through the GeoInvesting[™] Offerings is not a substitute for professional financial advice. You should always check with your professional financial, legal and tax advisors to be sure that any Securities, investments, advice, products and/or services featured by and through the GeoInvesting[™] Offerings, as well as any associated risks, are appropriate for you.